Cardiac safety of simultaneous anti-HER2 and anthracycline therapy

Mariam Jafri, Daniel Rea

Research output: Contribution to journalArticlepeer-review


A long established oncological dogma requires that trastuzumab should not be given in combination with anthracyclines due to excessive synergistic cardiac morbidity. However, trastuzumab has been recently granted a license in the neoadjuvant setting with concurrent anthracylines. We discuss the role of anti-HER2 agents in breast cancer and their associated toxicities. Anthracycline chemotherapies are a central component of most adjuvant and neoadjuvant breast cancer regimens. Cardiac toxicity due to anthracyclines is explored. Finally, in this article, we will discuss the evidence for concurrent administration of anthracyclines and HER2-targeted agents.
Original languageEnglish
Pages (from-to)21-29
JournalBreast Cancer Management
Issue number1
Publication statusPublished - Feb 2016


Dive into the research topics of 'Cardiac safety of simultaneous anti-HER2 and anthracycline therapy'. Together they form a unique fingerprint.

Cite this